Titre :

Non-hemorrhagic joint disorders and vitamin k antagonists: an under recognized adverse drug reaction?

Auteur(s) :

Bene, Johana [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Rousselin, Clementine [Auteur]
Université Lille Nord (France)
Bagheri, Haleh [Auteur]
Université Toulouse III - Paul Sabatier [UT3]
Vial, Thierry [Auteur]
Gautier, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lambert, Marc [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995

Titre de la revue :

Fundamental & Clinical Pharmacology

Nom court de la revue :

Fundam Clin Pharmacol

Numéro :

32

Pagination :

663-668

Date de publication :

2018-12

ISSN :

1472-8206

Mot(s)-clé(s) en anglais :

warfarin
acenocoumarol
adverse drug reaction
arthralgia
arthritis
fluindione

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Isolated arthralgia, without hemorrhagic side effect, exists and is considered as a very rare adverse drug reaction according to vitamin K antagonists' (VKAs) summary of product characteristics. Up to now, there are no ...
Lire la suite >Isolated arthralgia, without hemorrhagic side effect, exists and is considered as a very rare adverse drug reaction according to vitamin K antagonists' (VKAs) summary of product characteristics. Up to now, there are no literature reports of isolated, nonhemorrhagic joint complications in patients receiving VKAs. Hence, the objective of this study was to describe cases of VKA-related nonhemorrhagic joint disorders (fluindione, warfarin, and acenocoumarol) reported in the French Pharmacovigilance Database (FPVD). Sixty-one reports (male : female ratio, 1.18; median [interquartile range (IQR)] age: 60 [49-72]) were found. Fluindione, warfarin, and acenocoumarol were respectively suspected in 42, 12, and 7 cases. Arthralgia was reported in 47 cases (77%), arthritis in nine cases (15%), capsulitis in three cases (5%), and bursitis in two cases (3%). Although the joint symptoms mainly concerned the lower limbs, all types of joints were affected. Arthralgia was associated with myalgia in 14 cases and with tendinitis in three cases. The median (IQR) time interval between VKA introduction and arthralgia onset was 26 (10-98) days (range: 1-6935). VKA was withdrawn in 44 cases, and a decrease in the intensity of joint symptoms was observed in 30 cases. In three cases, reintroduction of the same VKA led to the recurrence of symptoms. In view of the large prescription of this drug class worldwide, patients and clinicians (and especially primary care physicians and geriatricians) should be aware of this possible adverse drug reaction when confronted with joint disorders in patients of all ages taking VKAs.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Troubles cognitifs dégénératifs et vasculaires

Date de dépôt :

2019-11-27T13:04:21Z
2023-12-08T13:16:31Z
2023-12-13T09:51:13Z